Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lysine hydrochloride + glucose is a pharmaceutical combination typically formulated as an injection, pairing the hydrochloride salt of the essential amino acid L-lysine with the monosaccharide glucose. This formulation is primarily utilized in clinical research and pharmaceutical analysis rather than as a standard first-line therapy. Research indicates that L-lysine can attenuate the blood glucose response when co-administered with glucose, potentially by stimulating endogenous insulin secretion or modulating glucose absorption. While glucose serves as a primary caloric energy source, the combination is explored for its potential applications in managing metabolic conditions where glucose regulation is impaired, though these findings remain largely in the research phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lysine hydrochloride + glucose.